Equities research analysts predict that Diplomat Pharmacy (NYSE:DPLO) will report earnings of $0.22 per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Diplomat Pharmacy’s earnings. The lowest EPS estimate is $0.19 and the highest is $0.28. Diplomat Pharmacy reported earnings of $0.19 per share in the same quarter last year, which would indicate a positive year over year growth rate of 15.8%. The firm is expected to issue its next quarterly earnings results on Monday, May 14th.
On average, analysts expect that Diplomat Pharmacy will report full-year earnings of $0.94 per share for the current year, with EPS estimates ranging from $0.90 to $0.96. For the next year, analysts anticipate that the business will post earnings of $1.12 per share, with EPS estimates ranging from $1.01 to $1.22. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Diplomat Pharmacy.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.18 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.02. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.17 billion. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The firm’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.08 earnings per share.
Several equities analysts have commented on DPLO shares. Needham & Company LLC increased their price target on shares of Diplomat Pharmacy from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, January 8th. Mizuho set a $25.00 price target on shares of Diplomat Pharmacy and gave the company a “hold” rating in a research note on Wednesday, January 24th. Credit Suisse Group upgraded shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 price target on the stock in a research note on Thursday, January 25th. Deutsche Bank lowered shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and increased their price target for the company from $22.00 to $29.00 in a research note on Friday, February 2nd. Finally, Lake Street Capital started coverage on shares of Diplomat Pharmacy in a research note on Friday, February 9th. They issued a “buy” rating and a $35.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $25.38.
In other news, Director Philip R. Hagerman sold 2,150,000 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $20.65, for a total transaction of $44,397,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 30.20% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Advisors Preferred LLC purchased a new position in shares of Diplomat Pharmacy during the fourth quarter worth approximately $162,000. SG Americas Securities LLC purchased a new position in shares of Diplomat Pharmacy during the third quarter worth approximately $191,000. Piedmont Investment Advisors LLC acquired a new stake in shares of Diplomat Pharmacy during the third quarter worth $216,000. Fox Run Management L.L.C. acquired a new stake in shares of Diplomat Pharmacy during the fourth quarter worth $244,000. Finally, ETRADE Capital Management LLC acquired a new stake in shares of Diplomat Pharmacy during the fourth quarter worth $276,000. Institutional investors and hedge funds own 63.73% of the company’s stock.
Shares of Diplomat Pharmacy stock opened at $19.80 on Tuesday. The company has a market capitalization of $1,450.28, a price-to-earnings ratio of 23.57 and a beta of 1.32. Diplomat Pharmacy has a 52 week low of $14.23 and a 52 week high of $27.78. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.66 and a current ratio of 0.97.
ILLEGAL ACTIVITY WARNING: “$0.22 EPS Expected for Diplomat Pharmacy (DPLO) This Quarter” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://ledgergazette.com/2018/04/20/0-22-eps-expected-for-diplomat-pharmacy-dplo-this-quarter.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.